Terug naar bedrijfspagina

Nieuws over ASIT biotech

25/11/2019 Asit biotech-primaire eindpunt fase III graspolallergie niet gehaald (25.11.2019)

14/06/2019 Asit Biotech - Notulen algemen vergadering (14.6.2019)

29/05/2019 ASIT biotech - documents Extraordinary General Shareholders Meeting on 28 June 2019 (29.5.2019)

27/05/2019 ASIT Biotech - to Participate in Multiple Upcoming Industry Events (27.5.2019)

05/03/2019 ASIT biotech reveals the mode of action of its lead immunotherapy product for Allergic Rhinitis, in ournal of Allergy and Clinical Immunology (5.3.2019)

25/02/2019 ASIT biotech is confident in the execution of its key priorities for 2019 (25.2.2019)

19/02/2019 ASIT biotech (19.2.2019)

31/01/2019 Asit-First patient treated with gp-ASIT+™ within the framework of confirmatory phase III test graspollen (31.1.2019)

16/01/2019 Asit biotech -Ongoing restructuring of ASIT biotech organization (16.1.2019)

19/12/2018 Asit Biotech-Verslag van de Algemene vergadering van 17 december 2018 en van de Raad van bestuur van 18 december 2018 (19.12.2018)

28/11/2018 ASIT biotech-Kepler Cheuvreux publishes an initiation of coverage report (28.11.2018)

19/11/2018 ASIT biotech launches its confirmatory Phase III clinical study with gp-ASIT+ in grass pollen prevention (19.11.2018)

08/10/2018 ASIT biotech receives the Best Biopharmaceutical Corporate Governance Belgium 2018 Award (8.10.2018)

19/09/2018 ASIT biotech presents its 2018 half-year results and provides an update on its clinical programs until end-2019 (19.9.2018

31/05/2018 Asit Biotech (Edison)

21/06/2017 Turbulentie in Belgische biotech: Celyad en ASIT Biotech (KBC Group, The Front Row)

08/05/2017 2017 05 - Interview biotechbedrijf ASIT